决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells.
间皮素(MSLN)在超过90%的恶性胸膜间皮瘤和胰腺腺癌中过表达,而在正常组织中表达极低,因此是一个理想的免疫治疗靶点。
间皮素(MSLN)在 >90 % 的恶性胸膜间皮瘤和胰腺腺癌中过表达,在正常组织中表达极低,是理想的免疫治疗靶点。这里,我们使用包含连接至 CD8 H/TM、4-1BB 和 CD3 信号结构域的单链可变片段的 CAR 构建体,生成了通用型脐带血(UCB)来源的抗 MSLN CAR-T。通过流式细胞术表征了 CAR 表达、T 细胞亚群和耗竭标志物。通过 alamarBlue 法评估了对 MSLN 阳性 NCI-H2452 和 MSLN 阴性 A431 细胞的细胞毒性(效靶比,0.5:1-5:1;持续 6-24 h),并使用酶联免疫吸附试验定量了细胞因子分泌(IL-2、IFN-、TNF-、IL-6)。在雌性 NOD/SCID/ c - / - 异种移植模型中评估了体内抗肿瘤活性,通过生物发光成像监测肿瘤负荷,并通过 Kaplan-Meier 法评估生存。实验进行三次重复,数据使用 GraphPad Prism 分析。UCB 单核细胞中的 CAR 转导效率在第 12 天达到 88.27 % 7.29 %。与第 3 天细胞相比,它们保留了更高的记忆细胞比例(Tscm:28.16 % 21.39 %),并且耗竭标志物表达低于外周血 T(PB-T)细胞(APC 抗人 CD269:8.41 % 0.64 % vs 4.42 % 1.25 %;PE 抗人 CD366:5.48 % 0.76 % vs 3.58 % 0.89 %;p < 0.05)。UCB 来源的抗 MSLN CAR-T 细胞对 NCI-H2452 细胞表现出剂量和时间依赖性细胞毒性,而对 A431 对照细胞活性极低。此外,与 PB-T 共培养相比,细胞因子分泌显著升高。在异种移植模型中,CAR-T 细胞显著延长了中位生存期。因此,UCB来源的抗MSLN CAR-T在体外和体内均表现出耗竭减少、记忆T细胞比例增加以及抗肿瘤效力增强。
Mesothelin (MSLN), overexpressed in >90 % of malignant pleural mesotheliomas and pancreatic adenocarcinomas, with minimal expression in normal tissue, represents an ideal immunotherapeutic target. Here, we generated universal umbilical cord blood (UCB)-derived anti-MSLN CAR-Ts using a CAR construct comprising a single-chain variable fragment linked to CD8 H/TM, 4-1BB and CD3 signaling domain. CAR expression, T cell subsets, and exhaustion markers were characterized via flow cytometry. Cytotoxicity against MSLN-positive NCI-H2452 and MSLN-negative A431 cells was assessed via alamarBlue assay (effector-to-target ratio, 0.5:1-5:1; for 6-24 h), and cytokine secretion (IL-2, IFN- , TNF- , IL-6) was quantified using enzyme-linked immunosorbent assay. In vivo anti-tumor activity was evaluated in female NOD/SCID/ c - / - xenograft models, with tumor burden monitored via bioluminescence imaging and survival through the Kaplan-Meier method. Experiments were performed in triplicate, with data analyzed using GraphPad Prism. CAR transduction efficiency in UCB mononuclear cells reached 88.27 % 7.29 % by day 12. Compared to day 3 cells, they retained higher memory cell proportions (Tscm: 28.16 % 21.39 %), and lower exhaustion marker expression than peripheral blood T (PB-T) cells (APC anti-human CD269: 8.41 % 0.64 % vs 4.42 % 1.25 %; PE antihuman CD366: 5.48 % 0.76 % vs 3.58 % 0.89 %; p < 0.05). UCB-derived anti-MSLN CAR-T cells exhibited dose- and time-dependent cytotoxicity against NCI-H2452 cells, with minimal activity against A431 controls. Moreover, cytokine secretion was significantly elevated compared to that in PB-T co-cultures. In xenograft models, CAR-T cells significantly prolonged median survival. Thus, UCB-derived anti-MSLN CAR-Ts showed reduced exhaustion, increased memory T cell proportions, and enhanced anti-tumor efficacy in vitro and in vivo.
MEMBER ACCOUNT
登录成功会直接打开下一页。